Streetbeat News

Stock Prices

PNR

Pentair (NYSE:PNR) reported Q2 2024 adjusted EPS of $1.22, beating the estimate of $1.14. Sales were $1.099 billion, surpassing the $1.095 billion estimate. This represents a 1.57% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:56 am

GPC

Genuine Parts (NYSE:GPC) reported Q2 2024 adjusted EPS of $2.44, missing the analyst estimate of $2.59. Sales were $5.963 billion, also missing the estimate of $6.047 billion. Despite the misses, sales increased by 0.81% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:56 am

KO

Coca-Cola (NYSE:KO) reported Q2 2024 earnings of $0.84 per share, beating the analyst estimate of $0.81. The company also reported sales of $12.4 billion, surpassing the $11.753 billion estimate. This represents a 3.58% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:55 am

MRK

Merck announced that its prophylactic monoclonal antibody, Clesrovimab, for Respiratory Syncytial Virus (RSV) disease has met its primary safety and efficacy endpoints.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:52 am

CLRB

Cellectar Biosciences' Iopofosine I 131 has exceeded its primary endpoint in a pivotal study for Waldenstrom's Macroglobulinemia, achieving a 56.4% major response rate and a 98.2% disease control rate in heavily pretreated patients.

Portfolio Pulse from charles@benzinga.com

July 23, 2024 | 10:51 am

CBU

Community Financial (NYSE:CBU) reported Q2 2024 adjusted EPS of $0.95, beating the $0.81 estimate. Sales were $183.799M, surpassing the $179.556M estimate and showing a 4.87% increase from last year's $175.263M.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:49 am

MEDP

Medpace Holdings shares are trading lower after the company reported mixed Q2 financial results and narrowed its FY24 revenue guidance with its midpoint below estimates.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:48 am

AVY

Avery Dennison has raised its FY24 adjusted EPS outlook from a range of $9.00 - $9.50 to $9.30 - $9.50, compared to the $9.41 estimate.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:48 am

MSCI

MSCI has reiterated its full-year 2024 guidance, including capital expenditures of $95M-$105M and free cash flow of $1.225B-$1.285B. The guidance is based on various macroeconomic assumptions and is subject to uncertainties.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:47 am

MRK

Merck announced that its Phase 2b/3 trial of Clesrovimab, an antibody designed to protect infants from Respiratory Syncytial Virus (RSV) disease, met all primary safety and efficacy endpoints.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:47 am